Company Profile A fast growing, fully integrated, research oriented pharmaceutical company with a Global presence Revenues in FY ` 7277 Mn (US $ 121 Mn) Domestic business contributes 64% and international business contributes 36% of the revenues Formulation business contributes 93% and API business contributes 7% of revenues Workforce of over R&D scientists field staff

Our Infrastructure Corporate Office at Santacruz (E), Mumbai 8 Manufacturing Facilities - 5 FDFs - 3 APIs R&D Centre at Navi Mumbai 29 C&Fs

Mfg. Facilities for FDFs LOCATIONDOSAGE FORMAPPROVALS GOA I TABLETS, CREAMS & OINTMENTS US-FDA, EU-GMP, TGA Australia, MCC South Africa, ANVISA - Brazil GOA IISTERILE PRODUCTS US-FDA, EU-GMP, MCC South Africa, TGA Australia GOA IIITABLETS US-FDA, EU-GMP, TGA Australia, WALUJTABLETSEmerging Markets BADDI TABLETS, LIQUID ORALS & TOOTHPASTES EU–GMP and Emerging Markets

API facilities Multi-ton : Patalganga (USFDA, TGA Australia approved) - Reactor Capacity: 500 to 5000 L Kilo Scale: Navi Mumbai (USFDA, TGA Australia approved) - Reaction Systems: 16 to 500 L - Total Reactor Volume: 1 cubic meters - Temperatures range: -55 to celsius Intermediates : Rabale - Reactor Capacity: 500 to 3000 L - Total Reactor Volume: 50 cubic meters

Research & Development US $ 10 Mn Investment in R&D set-up Spread over an area of 150,000 square feet and employs over 200 scientists and technical personnel 58 Patents filed - 38 for APIs - 20 for FDFs

Business Model Branded Generics - 8 Marketing Divisions - 18 Therapeutic Segments Brands APIs Regulated Markets - Generic Business - CRAMS - Alliances Emerging Markets - Branded Generics - Through Distributors - Alliance

 Ranked 27th by CMARC in Rx Ranking  Ranked 28th by AWACS in SSA Audit (Sept’14) 8 MARKETING DIVISIONS INDOCO GPs, CPs, Gynaec, Pediatrician SPADE GPs, CPs, Pediatrician, ENTs, Otologicals WARREN Dental EXCEL Opthalmic SPERA GPs, Gynaec, Pediatrician ETERNA CPs, Orthos, Gastro INDOCO CND Lifestyle / Cardio & Diabetology INSTITUTION Caters to Hospital & Government Supplies Indian Business

Growth Drivers (Domestic Business) Growing middle class population, increasing income levels, rapid urbanization, demand for quality healthcare services & changing lifestyle Focus on chronic segment Penetration in Northern and Eastern Regions New Products introductions (around 20 products every year) Growth above Industry Average

International Business Revenue of Rs Mn in FY14 (US $ 33 Mn) Revenue contribution UK 48%, USA 23 %, SA 12%, Germany 8%) CRAMS, Dossier Out-Licensing, Out-Licensing of MAs Actavis (Watson) Partnership Regulated Markets (85% of Formulation Export Business) Revenue of Rs. 307 Mn in FY14 (US $ 5 Mn) Revenue contribution Africa 8%, Asia 2%, Latam 2% Promotion of Branded Generics through Distributors Aspen Partnership Emerging Markets (15% of Formulation Export Business)

Strong Partnership with Watson Pharmaceuticals Inc., USA Multi-product, Multi-territory alliance with Aspen Pharmacare, SA Own filing of ANDAs and Dossiers NDDS and new technology platforms Growth Drivers (International Business)

Segment wise Break-up and Contribution

(` In Lacs) Profit & Loss A/C – Percentage to Net Sales Particulars Quarter Ended Half Year Ended Year Ended (Audited) % to Sales (Unaudited) % to Sales (Unaudited) % to Sales (Unaudited) % to Sales (Unaudited) % to Sales INCOME Net Sales / Income from Operations Add: Other Operating Income Total Income from Operations Add: Other Income Total Income EXPENDITURE Material Cost Employees Benefit Expenses Research & Development Expenses Other Expenses Finance Cost Depreciation and Amortisation Expenses Misc. Expenditure Written Off Total Expenses PBT Tax Expenses PAT EBIDTA (w/o R&D) EBIDTA (with R&D) Operating Profit